Drugs and patents in ATC class A07XA

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
MYTESI	crofelemer
>Tradename	>Generic Name

Last updated: June 23, 2026

ATC Class A07XA (Other antidiarrheals) is a low-to-mid unit category where exclusivity is fragmented across a mix of branded combination products, specialty anti-infectives used for diarrhea control, and formulation or method patents for symptomatic and gut-targeted therapies. Patent estates tend to cluster around (1) active ingredients that are not dominated by single-origin molecules, (2) microbiome and gut-absorption modulation concepts, and (3) delivery systems (extended release, gut-targeted release, or locally acting formulations). Generic entry risk is highest where Orange Book listings show mature patents expiring and where Paragraph IV filings have already been used as the primary entry play.

Bottom line for business: treat A07XA as a portfolio of smaller sub-markets rather than a single “one patent, one product” contest. The highest litigation density and most actionable generic timing typically sit in products with (a) Orange Book patent coverage for formulations or methods-of-use and (b) active FDA review or substitution pathways where challengers can target a narrow set of indications.

Which therapies fall under ATC A07XA “Other antidiarrheals,” and how fragmented is the patent estate?

Featured snippet answer: A07XA “Other antidiarrheals” is not a single drug class in practice; it is a catch-all grouping that spans multiple active ingredients and delivery concepts. The patent landscape is fragmented, with estates anchored by formulation, method-of-use, and sometimes dosing-regimen patents tied to diarrhea syndromes.

How A07XA is typically populated (commercial and patent-relevant view)

A07XA usually captures products that do not fit core diarrhea pillars like classic antimotility agents (ATC A07XA is “other”), antisecretory rehydration-adjacent therapies, or standard antibiotic categories under other A07 groupings. In operational patent work, the category breaks into three patent-driven sub-buckets:

Gut-targeted symptomatic controls
Patents often cover release profile, local action, and dosing schedules.
Adjuncts that modulate intestinal function
These include therapies that affect absorption, permeability, bile acid handling, inflammatory signaling, or microbiome-associated pathways. Patents tend to be method-of-use, patient population, or regimen-based.
Anti-infective or microbiota-directed diarrhea controls used beyond simple antimotility
Estates can include novel chemical entity or next-generation formulations plus manufacturing or process patents.

Why fragmentation matters for licensing and litigation

In A07XA, the same clinical endpoint (diarrhea reduction) can be achieved via multiple mechanisms. That reduces the value of broad “class” freedom-to-operate opinions. Patent risk assessments must map coverage at the product and even indication level, not just at “diarrhea” level.

What patents protect A07XA products: composition, formulation, and method-of-use coverage?

Featured snippet answer: Patent protection in A07XA concentrates on formulation (release/delivery), method-of-use (patient population and regimen), and sometimes process/manufacturing steps. Composition-of-matter is present but often not the dominant risk driver late in lifecycle.

Patent types that show up most often in A07XA exclusivity

Formulation and delivery system patents
- Extended release, delayed release, or gut-targeted release systems
- Matrix or coating systems to control local drug concentration
- Dosage strength and ratio-specific compositions
Method-of-use patents
- Specific diarrhea subtypes (infectious diarrhea, antibiotic-associated diarrhea, IBS-D-like phenotypes when included in labeling, or other defined syndromes)
- Treatment timing (initiation window), dosing frequency, and response-guided titration
Manufacturing and process patents
- Solid-state processes affecting particle size, polymorph control, or stability
- Layered tablet or capsule manufacturing methods for targeted release
Combination and fixed-dose ratio patents
- When the marketed product uses a combination approach, ratio-specific claims and combination regimen claims can survive composition expiry

Practical litigation consequence

Method-of-use and formulation claims produce “design-around” constraints that do not exist when only composition is claimed. For generic entrants, label alignment and formulation equivalence become decisive.

When does exclusivity end for A07XA drugs: how do patent and regulatory milestones line up?

Featured snippet answer: Exclusivity timing in A07XA is driven by the later-expiring item among (1) primary patents on active ingredients, (2) formulation patents, (3) method-of-use patents, and (4) any regulatory exclusivity periods. The market typically sees delayed generic entry when formulation and method patents survive past the core composition.

Milestone map that matters for generic launch planning

A generic entry timeline is most impacted by this sequence:

NCE or key filing date → composition patent expiry horizon
Formulation innovation (often filed later) → extends practical exclusivity
FDA labeling and submission → controls whether method-of-use patents are enforceable at launch
Orange Book patent list maturity → determines whether Paragraph IV is available and actionable
Exclusivity periods tied to approval (when applicable) → overlays with patent expiry

Business implication

For A07XA, “close to composition expiry” does not equal “generic open season.” Teams should prioritize building a patent ladder map that orders claims by (a) jurisdiction, (b) claim type, and (c) expiration date.

How many patents cover A07XA products, and how long do they typically last across jurisdictions?

Featured snippet answer: Patent counts vary widely by product, but A07XA estates commonly include multiple follow-on filings for formulation and method-of-use, keeping active claim sets in force into later years even after the original patent family.

Portfolio behavior patterns

High follow-on density: gut-targeted delivery and formulation improvements
Lower follow-on density: older, single-generation actives with limited new dosage forms
Geographic skew: the US is where Orange Book-listed patents drive litigation posture; EP and JP can still limit manufacturing scale-down even if US composes the legal fight

What that means for freedom-to-operate

FTO in A07XA should be assessed at:

US (Orange Book patents + FDA labeling constraints)
Key export markets where manufacturing occurs
At least one enforcement-heavy jurisdiction if commercial footprint supports litigation risk

What Paragraph IV challenges are likely in A07XA, and what do they signal about generic timing?

Featured snippet answer: Paragraph IV behavior in A07XA signals the presence of Orange Book-listed patents with reasonable enforceability and clear “product-to-patent” mapping. When challenges occur, they usually target formulation or method-of-use listings rather than only core composition.

Generic risk signals that matter most

Multiple Orange Book listings with active claim periods
Known method-of-use claims tied to labeled indications
Late-stage formulation patents with expiration after core patent families
Repeat challenger entries (indicating challengers see non-obvious carve-out opportunities)

Settlement patterns to expect

In A07XA, settlements often aim to:

delay generic launch until a later formulation or method patent expires
permit entry with limited strengths or narrow indication scope
lock in labeling carve-outs to avoid infringement

What is the Orange Book status of A07XA “other antidiarrheals,” and which patent listings drive the litigation calendar?

Featured snippet answer: Orange Book status is product-specific and typically dominated by formulation and method-of-use patent listings that extend beyond the first composition patent expiry. The Orange Book listing set determines both Paragraph IV eligibility and the scope of triggered infringement theories.

How to read Orange Book for A07XA entry planning

Start from the FDA reference product and list all Orange Book patents tied to:
- drug substance
- drug product (formulation)
- method-of-use (if present)
Rank by expiration date and claim type, then overlay with existing Paragraph IV litigation timelines.

What patent litigation affects A07XA drugs: who sues whom, and what claims are usually asserted?

Featured snippet answer: A07XA litigation typically asserts:

formulation and delivery system claims for the generic’s product,
method-of-use claims based on labeled dosing and indication,
process claims where manufacturing alternatives can be constrained.

Litigation posture that shapes generic strategy

If plaintiffs win early on claim construction, generics pivot to design-around.
If courts narrow asserted claims, generics often accelerate launch with a constrained formulation.
Settlement frequently reflects uncertainty about method-of-use claim scope and labeling enforceability.

Which generic entry risks exist for A07XA: what happens at the moment exclusivity breaks?

Featured snippet answer: Generic entry risk spikes when the last enforceable formulation or method-of-use patent expires and when labeling supports a non-infringing indication or dosing regimen.

Launch scenarios common in A07XA

Full-label generic entry
- Only when both formulation and method-of-use claims are cleared or expired.
Carve-out label entry
- Generic enters for a narrower diarrhea subtype or dosing window to avoid method-of-use infringement.
Strength or dosage form limitations
- If formulation patents are dosage-form specific, launch may be blocked for certain strengths.
Manufacturing process workarounds
- If process patents are asserted, generics may shift manufacturing route, but only after proving non-infringement in litigation or via covenant practice.

How does A07XA compare with other ATC antidiarrheals (A07AA, A07AB, A07AC, A07AD) in patent defensibility?

Featured snippet answer: Compared with core antimotility or antisecretory ATC buckets, A07XA tends to have more formulation and method follow-on patents and less single-dominant blockbuster coverage, which increases competitive entry variance.

Key comparison dimensions

Claim diversity: A07XA more often relies on delivery and regimen differentiation.
Litigation spread: A07XA can show multiple small disputes rather than one dominant case.
Design-around feasibility: higher, but method-of-use claims can still create high enforcement friction.

Which companies hold the strongest A07XA patent estates, and how should portfolios be prioritized?

Featured snippet answer: The “strongest” estates in A07XA belong to companies with (1) late-stage formulation follow-ons and (2) Orange Book-listed method-of-use claims aligned to key labeled diarrhea indications. Prioritization should track which company families still have active patent endpoints controlling generic entry.

Portfolio prioritization logic

For licensing or acquisition:

prioritize drug product and method-of-use families that expire last
prioritize jurisdictions where enforcement occurs and where manufacturing is constrained
prioritize products with active FDA labeling and clear claims mapping to the marketed use

Revenue exposure: how much of A07XA depends on patent-protected products versus mature compounds?

Featured snippet answer: A07XA revenue exposure is usually concentrated in a small number of branded products with defensible follow-on formulation or method patents. Mature compounds without active Orange Book coverage tend to face earlier price erosion and generic competition.

Exposure drivers for investors and business development

concentration risk: a few patents can govern multiple years of profit
downside risk: late-expiring formulation patents create step-function entry risk at specific expiry windows
upside risk: method-of-use carve-outs can preserve value even if some patent elements expire

Manufacturing and IP barriers: what non-clinical patents block generic or biosimilar-like substitutes in A07XA?

Featured snippet answer: Manufacturing patents can block generic substitutes even when clinical method-of-use or composition claims are weak, especially when solid-state or process claims are enforceable and when drug product specifications are tightly controlled.

Barriers that matter operationally

validated particle size, polymorph, or stability targets tied to process patents
coating and release-layer manufacturing controls
stability and shelf-life specifications linked to formulation IP

Key takeaways on the A07XA patent and market dynamics map

A07XA exclusivity is fragmented across mechanisms and delivery systems, not anchored to a single class-wide patent profile.
Patent protection most often persists via formulation and method-of-use follow-ons, not only primary composition claims.
Generic launch risk rises sharply when the last Orange Book-listed formulation and method-of-use patents expire or are cleared in litigation.
Orange Book status and label-to-claim mapping are the gating factors for Paragraph IV strategy in A07XA.
Business planning should treat A07XA as a portfolio of product-specific patent ladders with different litigation calendars and settlement outcomes.

FAQs

1) Which “other antidiarrheals” patents typically extend exclusivity beyond the drug substance?

Formulation (drug product) and method-of-use patents aligned to labeled diarrhea subtypes and regimens.

2) Do A07XA method-of-use claims drive most Paragraph IV disputes?

They often do when they are Orange Book-listed and tightly aligned to dosing/indication in the reference product labeling.

3) Can generics enter A07XA markets with label carve-outs?

Yes, carve-out launches are a common settlement and court-driven outcome when method claims are enforceable only for specific labeled uses.

4) What formulation elements are usually targeted in A07XA generics?

Release profile, coatings/matrices controlling local intestinal action, and dose form design that maps to drug product patent claims.

5) Where should manufacturing/IP risk be assessed for A07XA FTO?

At least at the US claim set tied to Orange Book patents and in the key manufacturing-export jurisdictions where process and solid-state patents can still be enforced.

References (APA)

No sources were cited because no specific A07XA active ingredients, FDA product entries, Orange Book listings, patent numbers, or litigation dockets were provided in the input.